TCGA-AN-A0FY-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V2+0.490
- MYC_TARGETS_V1+0.420
- HEDGEHOG_SIGNALING+0.300
- MITOTIC_SPINDLE+0.290
- DNA_REPAIR+0.240
- ESTROGEN_RESPONSE_EARLY+0.200
- TGF_BETA_SIGNALING+0.200
- ESTROGEN_RESPONSE_LATE+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.440
- ALLOGRAFT_REJECTION-0.360
- KRAS_SIGNALING_UP-0.360
- NOTCH_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- INFLAMMATORY_RESPONSE-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- COMPLEMENT-0.310
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0006_T1_RNA | — | B | 0.865 |
| 2 | BS_1AYRM596 | medulloblastoma | — | 0.860 |
| 3 | ad30e5e1-182b-4758-8e70-53e0bcf78072 | — | — | 0.860 |
| 4 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.853 |
| 5 | TCGA-77-8128-01A-11R-2247-07 | — | cohortSQ2 | 0.853 |
| 6 | TCGA-77-8139-01A-11R-2247-07 | — | cohortSQ1 | 0.849 |
| 7 | TCGA-77-A5G3-01A-31R-A27Q-07 | — | cohortSQ2 | 0.847 |
| 8 | AUR-AD9E-TTM1-A-1-1-R-A542-39 | — | B | 0.843 |
| 9 | R399 | — | — | 0.836 |
| 10 | SRR8613800 | — | D | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |